Pulmonology

18.7 percent of U.S. adults reported any tobacco product use in 2021; 77.5 percent of those using tobacco products reported combustible product use

Arexvy was ~82 percent effective in preventing RSV-induced lower respiratory tract infections in adults 60 years of age and older

Moderate net benefit found for preventing active tuberculosis disease by screening persons at increased risk for infection

Moderate net benefit found for preventing active tuberculosis disease by screening persons at increased risk for infection

Integration of definitive local therapy relevant if technically feasible and clinically safe to all disease sites

Benefits seen in terms of pathologic complete response and event-free survival for resectable non-small cell lung cancer

In adjusted analysis, 31 percent of people with concurrent diseases died

Significant improvements seen in pulmonary hemodynamics and functional capacity

Additionally, chronic disease prevalence higher in the incarcerated population

Chatbot generates higher proportion of responses rated as good or very good quality and empathetic or very empathetic than physicians